Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Clinical Pathology

• Publication date

  2018-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jclinpath-2018-205143PMID 29703758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Three case reports

  2019cited by this paper
• Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors

  2019cited by this paper
• Toxicities associated with checkpoint inhibitors—an overview

  2019cited by this paper
• Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.

  2019cited by this paper
• Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

  2018cited by this paper
• Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management

  2018cited by this paper
• Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors

  2017cited by this paper
• Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management

  2017cited by this paper
• Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies

  2017cited by this paper
• Immune modulator‐induced changes in the gastrointestinal tract

  2017cited by this paper
• PD‐1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’

  2017cited by this paper
• Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis.

  2017cited by this paper
• Immune checkpoint inhibitor colitis: the flip side of the wonder drugs

  2017cited by this paper
• Histopathology of pembrolizumab-induced hepatitis: a case report.

  2017cited by this paper
• corrigenda to Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [Ann Oncol 26 (2015) 2375-2391, doi: 10.1093/annonc/mdv383]

  2016cited by this paper
• Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

  2016cited by this paper
• Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.

  2016cited by this paper
• Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

  2016cited by this paper
• Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

  2016cited by this paper
• Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

  2016cited by this paper
• Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.

  2016cited by this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Anti-PD1-induced collagenous colitis in a melanoma patient.

  2016cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Idelalisib-associated Colitis: Histologic Findings in 14 Patients

  2015cited by this paper
• Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases

  2015cited by this paper
• Systematic review: colitis associated with anti‐CTLA‐4 therapy

  2015cited by this paper
• Toxicities of Immunotherapy for the Practitioner.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists

  2014cited by this paper
• Ipilimumab associated hepatitis: imaging and clinicopathologic findings

  2013cited by this paper
• Ipilimumab and its toxicities: a multidisciplinary approach.

  2013cited by this paper
• Ipilimumab-induced perforating colitis.

  2013cited by this paper
• Lymphocytic colitis secondary to ipilimumab treatment.

  2013cited by this paper
• Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

  2013cited by this paper
• Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Pointers and pitfalls of mycophenolate-associated colitis

  2012cited by this paper
• Lymphocytic Colitis and Collagenous Colitis: A Review of Clinicopathologic Features and Immunologic Abnormalities

  2012cited by this paper
• Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

  2010cited by this paper
• The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

  2010cited by this paper
• Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

  2009cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• α-CTLA-4 mAb-associated Panenteritis: A Histologic and Immunohistochemical Analysis

  2008cited by this paper
• Mycophenolate Mofetil-related Gastrointestinal Mucosal Injury: Variable Injury Patterns, Including Graft-versus-Host Disease-like Changes

  2008cited by this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper

• Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications

  2026cites this paper
• Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.

  2025cites this paper
• Immune checkpoint inhibitor-related gastrointestinal adverse events: a disproportionality analysis based on the FAERS database.

  2025cites this paper
• Exacerbation of previously undetected ulcerative colitis in a patient undergoing nivolumab for metastatic melanoma: A case report.

  2025cites this paper
• Immunotherapy-Induced Hepatitis Mimicking Sclerosing Cholangitis in a Patient With Metastatic Triple-Negative Breast Cancer

  2025cites this paper
• Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)

  2025influential citation
• Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report.

  2025cites this paper
• Cemiplimab‐Induced Colitis Causing Hypovolemic Shock: A Case Report and Literature Review

  2025cites this paper
• Emerging Manifestations of IL-17 Immunomodulation in the Gastrointestinal Tract.

  2025cites this paper
• Title-Rare Case of Retroperitoneal Colon Perforation in Advanced Squamous Cell Carcinoma of Kidney

  2025cites this paper
• An updated review on immune checkpoint inhibitor-induced colitis: epidemiology, pathogenesis, treatment strategies, and the role of traditional Chinese medicine

  2025cites this paper
• Checkpoint inhibitor colitis: a gastroenterologists’ perspective

  2025cites this paper
• Management of Crohn’s Disease and Ulcerative Colitis Flare, Possibly Induced by Nivolumab Therapy: Two Cases and Review of The Literature

  2024cites this paper
• Immune checkpoint inhibitor-related colitis in patients on immunotherapy for cancer.

  2024cites this paper
• Esophageal lymphocytosis: exploring the knowns and unknowns of this pattern of esophageal injury

  2024cites this paper
• The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis.

  2024cites this paper
• Colitis associated with persistent drug-induced immune dysregulation

  2024cites this paper
• PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

  2024cites this paper
• Immunophenotyping to improve the mechanistic understanding of idiosyncratic drug-induced liver injury: clinical implications and future directions

  2023cites this paper
• Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects

  2023cites this paper
• Immune Checkpoint Inhibitor-Induced Liver Injury

  2023cites this paper
• Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management

  2023cites this paper
• Histopathologic Manifestations of Immune Checkpoint Inhibitor Therapy-Associated Gastrointestinal Tract Injury: A Practical Review.

  2023cites this paper
• Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature

  2023cites this paper
• Liver Pathology Related to Onco-Therapeutic Agents.

  2023cites this paper
• Toxicidad por inmunoterapia en cáncer: una visión oncológica para el internista

  2023influential citation
• Accelerated curation of checkpoint inhibitor-induced colitis cases from electronic health records

  2023cites this paper
• Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus.

  2023cites this paper
• Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists

  2022cites this paper
• Immune-related colitis and pancreatitis treated with infliximab

  2022cites this paper
• Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.

  2022cites this paper
• Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports

  2022cites this paper
• Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review

  2022cites this paper
• Lymphocyte-Predominant Esophagitis Rarely Improves With Proton Pump Inhibitor Therapy

  2022cites this paper
• Drug Induced Digestive tract Injury: Decoding some invisible offenders.

  2022cites this paper
• Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer

  2022cites this paper
• Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

  2022cites this paper
• Immunotherapy-induced Colitis

  2022cites this paper
• The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy

  2022cites this paper
• Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM

  2022cites this paper
• Immune checkpoint inhibitor colitis with concurrent cytomegalovirus reactivation

  2022cites this paper
• PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.

  2022cites this paper
• Checkpoint Inhibitors and Induction of Celiac Disease-like Condition

  2022cites this paper
• Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

  2021cites this paper
• Practical Gastrointestinal Pathology: Frequently Asked Questions

  2021cites this paper
• Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab

  2021cites this paper
• Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review

  2021cites this paper
• A close view on histopathological changes in inflammatory bowel disease, a narrative review

  2021cites this paper
• Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.

  2021cites this paper
• Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist.

  2021cites this paper
• Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review

  2021cites this paper
• Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment

  2021cites this paper
• Sclerosing cholangitis in a patient treated with nivolumab

  2021cites this paper
• Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

  2021cites this paper
• Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis

  2021cites this paper
• Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry

  2021cites this paper
• Deciphering the Dynamic Complexities of the Liver Microenvironment — Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI)

  2021cites this paper
• Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer

  2021cites this paper
• Pathological complete response to pembrolizumab in patients with metastatic ascending colon cancer with microsatellite instability

  2021cites this paper
• The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma

  2021cites this paper
• Delayed immune-related neutropenia with hepatitis by pembrolizumab.

  2021cites this paper
• Mechanisms of immune checkpoint inhibitor-mediated liver injury

  2021cites this paper
• Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

  2021cites this paper
• Immunotherapy-Mediated Luminal Gastrointestinal Toxicities.

  2021cites this paper
• Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature

  2021cites this paper
• Immune Related Adverse Events

  2020cites this paper
• Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.

  2020cites this paper
• Remission of ulcerative colitis flare-up induced by nivolumab

  2020cites this paper
• Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience

  2020cites this paper
• Lymphocytic colitis-pattern of injury presenting as endoscopic polyps: case series.

  2020cites this paper
• Immune-related adverse events of checkpoint inhibitors

  2020cites this paper
• Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy.

  2020cites this paper
• ИНГИБИТОРЫ КОНТРОЛЬНЫХ ТОЧЕК ИММУННОГО ОТВЕТА: НОВЫЕ РИСКИ НОВОГО КЛАССА ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ

  2020cites this paper
• Management of gastrointestinal perforation related to radiation

  2020cites this paper
• Hepatobiliary Adverse Events.

  2020cites this paper
• Gastrointestinal Tract Adverse Events.

  2020cites this paper
• Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.

  2020cites this paper
• [An unusual digestive complication under anti-PD-1 (pembrolizumab)].

  2020cites this paper
• Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.

  2020cites this paper
• Pembrolizumab‐related pancreatitis with elevation of pancreatic tumour markers

  2020cites this paper
• Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

  2020cites this paper
• Pathology in Patients with Chronic Liver Disease: A Practical Approach to Liver Biopsy Interpretation in Patients with Acute and Chronic Liver Diseases.

  2020cites this paper
• British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.

  2020cites this paper
• Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

  2020cites this paper
• Immune checkpoint inhibitors induced colitis, stay vigilant: A case report

  2020cites this paper
• Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics

  2020cites this paper
• Hepatotoxicity induced by PD-1 inhibitors in cancer treatment

  2020cites this paper
• Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.

  2020cites this paper
• Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.

  2020cites this paper
• Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.

  2020cites this paper
• Collagenous colitis and atezolizumab therapy: an atypical case

  2020influential citation
• The significance of histological activity measurements in immune checkpoint inhibitor colitis

  2020cites this paper
• Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.

  2020influential citation
• Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting.

  2020cites this paper
• Drug-Induced Gastrointestinal Tract Injury

  2020cites this paper
• Non-Barrett Esophagitis

  2020cites this paper
• Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.

  2020cites this paper
• Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

  2020cites this paper
• Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.

  2019cites this paper
• Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment

  2019cites this paper